Stem Cell Clinic

Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS – Business Wire

By Stem Cell Medicine

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA (Promethera) and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a business alliance agreement. In conjunction with todays alliance, MEDIPAL has decided to increase its shareholdings in the Promethera Group. Details follows below.

The purpose of this alliancePromethera has been developing its lead liver cell-derived technology (HepaStem) in an area of high medical need, primarily for Non-alcoholic steatohepatitis (NASH), Acute-on-chronic liver failure (ACLF) and urea cycle disorder (UCD). Promethera completed the recruitment of 24 patients in its Phase 2a study in Acute-on-chronic liver failure (ACLF) in July 2019. The 3 months follow-up data were presented on 10th November at the AASLD 2019 conference (70th American Association for the Study of the Liver Diseases). In addition, the Phase 2a clinical study in patients with late stage NASH with worlds first cell therapy was initiated in May 2019. MEDIPAL will support Promethera in the commercialization of its products in Japan through the subscription to a private placement of new shares on March 20th, 2019, with the aim to expand the products it handles in the regenerative medicine field going forward.

The purpose of this alliance is to further deepen the cooperative relationship between the two companies by providing access to MEDIPALs know-how and capabilities in the distribution of cellular medicines at ultra-low temperatures. MEDIPAL will support Promethera's clinical trials and aims to provide a steady supply after its product launch.

With about 430 cases per year, the percent of patients receiving a liver transplant in Japan is significantly lower than in the US, where some 8,000 patients receive a transplant every year. Rescue solutions for Japanese patients with fatal liver diseases are performing poorly too. An even closer partnership with MEDIPAL will support us in setting up clinical trials in Japan that could positively impact and contribute to a solution for this considerable medical need in Japan. Building on this partnership, we will accelerate the clinical development of HepaStem towards a subsequent market launch in Japan, which will be a meaningful new development for Japanese patients suffering from end-stage liver disease, said Dr John Tchelingerian, President and CEO of Promethera. Mastering the entire supply chain is a key requirement for an off-the-shelf allogeneic cell therapy product, and MEDIPALs expertise and capabilities in this sector will be very valuable in this regard.

Prometheras HepaStem program can potentially become the worlds first therapeutic product using liver stem cells for the treatment of severe liver diseases, commented Shuichi Watanabe, Chief Executive Officer of MEDIPAL. Liver disease prevalence is rising in Japan and around the world due to an increase in obesity and other metabolic syndromes. The need to deliver effective treatments such as Prometheras is expected to augment rapidly. MEDIPALs system enables strict temperature management and traceability by using SDDU (Specialty Drug Distribution Unit: a liquid nitrogen-based ultra-low cold chain system for drug distribution) and has an extensive expertise in this field. We are very pleased with this partnership and the opportunity to support the development and the logistics of this innovative product candidate with our capabilities.

About MEDIPAL HOLDINGS CORPORATION

Head office

2-7-15, Yaesu Chuo-ku Tokyo 104-8461 Japan

Representative

Shuichi Watanabe, Representative Director, President and CEO

Business

As a holding company, MEDIPAL controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.

Website

https://www.medipal.co.jp/english

About Promethera Biosciences S.A.

Head office

Watson & Crick Hill, Rue Granbonpr, 11 B-1435 Mont-Saint-Guibert, Belgium

Representative

John Tchelingerian, PhD, President & CEO

Business

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Promethera develops and manufactures allogeneic cell-based medicines for liver diseases by using regenerative medicine technology.

Website

https://www.promethera.com/

See the original post here:
Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS - Business Wire

New Drug Benefits Patients With Myeloma Who Are Resistant to All Therapies – Dana-Farber Cancer Institute

By Stem Cell Medicine

Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of currently available therapies, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies.

A clinical trial found that 26.2 percent of such patients responded with significant shrinkage of their disease, including complete responses, and a median survival of 8.6 months despite their highly refractory disease.

The drug, selinexor or XPOVIO, developed by Karyopharm Therapeutics of Newton, Massachusetts, is a pill given with low-dose dexamethasone. Its currently being tested in a larger trial in combination with other drugs, such as bortezomib, to determine if it can improve outcome in myeloma.

Its novel mechanism of action and ability to overcome highly resistant disease is striking, says Paul Richardson, MD, clinical program leader and director of clinical research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber, and co-senior author of a report on the study in The New England Journal of Medicine. He and other Dana-Farber investigators were involved in the preclinical and clinical research on selinexor.

The accelerated approval of oral XPOVIOmarks an important advance in the treatment paradigm for patients with relapsed refractory multiple myeloma and in my view the drug is an important addition to our therapeutic armamentarium, says Richardson.

Selinexor is the first in a class ofdrugs that bind to a molecule called exportin 1 and block the transport ofseveral cancer-growth proteins from the cell nucleus to the cytoplasm. The drugalso activates tumor-suppressor proteins in the nucleus, leading to apoptosis,or self-destruction, of the cancer cell.

Selinexor earned accelerated approved by the FDA in July 2019 for patients with relapsed or refractory multiple myeloma who received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody drug.

Patients matching this description are known as triple-class refractory, meaning they did not respond satisfactorily to the three main classes of drugs used to treat myeloma. Survival for these patients is extremely short.

The clinical study report in The New England Journal of Medicine published in August included122 patients who had received a median of seven previous treatment regimensincluding chemotherapy, targeted therapy with bortezomib, carfilzomib,lenalidomide, pomalidomide, and monoclonal antibody (daratumumab). Almost allhad undergone stem cell transplant.

Their median age was 65.2 years and had myeloma for a median of 6.6 years; their disease was rapidly worsening, and they were out of options. These individuals represented the growing population of patients who have exhausted available therapies but want to continue with active therapy, say the researchers.

A partial response or better was seen in 26% of patients, including two complete responses (disappearance of the myeloma protein in their blood) and six very good partial responses, and 39% had a minimal response or better. The median duration of response was 4.4 months, median progression-free survival was 3.7 months, and median overall survival was 8.6 months, though in patients who responded the median survival was 15.6 months. Although there was no control group in the study, as in this setting such an approach is very problematic and lacks equipoise, Richardson says that historically, patients like those in the trial have a survival of only two to three months.

Because the window of time to treat such patients was closing rapidly, says Richardson, they started on a high dose of selinexor, with the researchers anticipating the need to reduce doses if adverse effects occurred. This proved to be the case, with 80% of patients having dose modification or interruption because of adverse events. Fatigue, nausea, and decreased appetite were common and low platelet counts occurred in 73% of patients, anemia in 44% of patients, and 22% had low blood sodium levels.

Richardson says the side effects proved manageable with careful supportive care required in this group of patients who were otherwise very ill and had no other treatment options. He notes the FDA approval was based not only on the results of this study, called STORM, but also on early indications of safety from the phase 3 BOSTON study which was recently completed to enrollment.

Continued here:
New Drug Benefits Patients With Myeloma Who Are Resistant to All Therapies - Dana-Farber Cancer Institute

Silencing Of MAGI1 Promotes The Proliferation And Inhibits Apoptosis O | OTT – Dove Medical Press

By Stem Cell Medicine

Yongzhi Lu,1 Wei Sun,2 Liang Zhang,3 Junyao Li4

1Department of Oncology, Qingdao Municipal Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China; 2Department of Neurology, Qingdao Third Peoples Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China; 3Department of Critical Care Medicine, Qingdao Eighth Peoples Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China; 4Department of Emergency, Qingdao Municipal Hospital, Qingdao, Shandong Province 266000, Peoples Republic of China

Correspondence: Junyao LiDepartment of Emergency, Qingdao Municipal Hospital, Qingdao, Shandong Province 266000, Peoples Republic of ChinaEmail wmy_188@126.com

Background: Membrane-associated guanylate kinase (MAGUK) with inverted orientation protein 1 (MAGI1) is a novel member of the MAGUK family with a vital role in tumor progression related to invasion and metastasis. However, the function of MAGI1 in glioma is currently unknown. We therefore analyzed the expression of MAGI1 protein in human glioma samples, glioma cell lines and glioma stem cells (GSCs), and explored its effects on glioma cell proliferation and apoptosis.Methods: MAGI1 expression in glioma tissues was examined by Western blotting and real-time polymerase chain reaction and its relationships with clinical pathological features were analyzed. The effects of MAGI1 knockdown on the proliferation of glioma cell lines and GSCs were detected by CCK8 and colony-formation assays, and apoptosis was assessed by flow cytometry. We also investigated the effects of MAGI1 silencing on protein expression levels of epithelial-mesenchymal transition biomarkers, as well as -catenin, cyclin D1, PTEN and phospho-Akt by Western blotting.Results: MAGI1 was significantly downregulated in glioma tissues and its expression was related to cancer progression. Silencing of MAGI1 in both glioma cell lines and GSCs enhanced proliferation and inhibited apoptosis. MAGI1 knockdown also significantly increased the expression levels of N-cadherin, vimentin, -catenin, cyclin D1 and phospho-Akt and reduced the expression of E-cadherin and PTEN.Conclusions: Our results indicated that MAGI1 might play a vital role in glioma progression and may represent a potential therapeutic target for the treatment of glioma.

Keywords: glioma, MAGI1, -catenin, EMT, proliferation, knockdown

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more here:
Silencing Of MAGI1 Promotes The Proliferation And Inhibits Apoptosis O | OTT - Dove Medical Press

Stem Cell Banking Market 2019: Growth, Trends, Demand, Share, Analysis and Forecast to 2026 – Markets Gazette 24

By Stem Cell Medicine

Stem Cell Banking Marketis expected to reachUSD 5830.41 Million by 2026 fromUSD 1593.9 Million in 2017 during the forecast period. A stem cell bank is a facility, which stores stem cells for future use. Stem cell banking is the process of conserving stem cells at temperatures below the freezing point. These cells used for the treatment of Parkinsons syndrome, cancer, diabetes, heart diseases, and others.

Stem cell banking market is segmented by Type, Banking service, Application, and Geography. Based on service type the sample preservation & storage segment is expected to hold maximum market share during the forecast period due to the increasing adoption of stem cell banking services in key countries, growing numbers of stem cell banks across developing countries, increasing public consciousness about the therapeutic applications of stem cells.

On the basis of application, the personalized banking applications segment is fastest-growing segment owing to increasing adoption of precision medicine across established countries, the growing prevalence of blood & immune system-related disorders amongstnew-borns& children, &growing public worries regarding the clinical abuse of stored stem cell samples.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/13540

North America is expected to hold largest market share during the forecast period. The increasing network of stem cell banking services, ongoing support of stem cell lines for various disease treatment, new technological developments in the field of stem cell collection & preservation techniques, increasing public-private investments for stem cell researches, rising number of stem cell transplantation procedures are pouring the growth of the Stem Cell Banking Market in North America.

Cordlife introduced NICE, a clinically approved non-invasive prenatal test in Indonesia and the Philippines.LifeCodexx AG, a Provider of non-invasive prenatal DNA testing in Europe, declared its partnership with LifeCell International Pvt. Ltd., an Indian mother & baby preventive health care Type, to bring PrenaTesT, qNIPT testing for the first time to India. The qNIPT technology, which detects the presence of foetal trisomy 21 (Down Syndrome) from maternal blood, received CE marking (European Conformity) in December 2016.

Cordlife Group Limited and China Cord Blood Corporation announced that the two companies collaborated in order to support patients across the China, Singapore, Hong Kong, Indonesia, India, the Philippines, and Malaysia to identify suitable cord blood matching units for stem cell therapy.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/13540

Scope of the report Stem Cell Banking Market:

Stem Cell Banking Market by Type:

Umbilical Cord Stem Cell Adult Stem CellEmbryonic Stem Cell Stem Cell Banking Market by Service Type

Storage Analysis Processing Collection & Transportation Stem Cell Banking Market by Application

Cerebral Palsy Thalassemia Cancer Diseases Diabetes Autism Stem Cell Banking Market by region

North America Europe APAC Latin America MEAKey Players Stem Cell Banking Market:

1. CCBC2. CBR Systems, Inc.3. ViaCord4. Esperite5. Vcanbio6. Boyalife7. LifeCell8. Crioestaminal9. RMS Regrow10. Cryo-cell11. Cordlife Group12. PBKM FamiCord13. Cells4life14. Beikebiotech15. StemCyte

MAJOR TOC OF THE REPORT

Chapter One: Stem Cell Banking Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Stem Cell Banking Market Competition, by Players

Chapter Four: Global Stem Cell Banking Market Size by Regions

Chapter Five: North America Stem Cell Banking Revenue by Countries

Chapter Six: Europe Stem Cell Banking Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Banking Revenue by Countries

Chapter Eight: South America Stem Cell Banking Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Stem Cell Banking by Countries

Chapter Ten: Global Stem Cell Banking Market Segment by Type

Chapter Eleven: Global Stem Cell Banking Market Segment by Application

Chapter Twelve: Global Stem Cell Banking Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Stem Cell Banking Market Report at:https://www.maximizemarketresearch.com/market-report/stem-cell-banking-market/13540/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email:sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read the rest here:
Stem Cell Banking Market 2019: Growth, Trends, Demand, Share, Analysis and Forecast to 2026 - Markets Gazette 24

4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress – Montana Ledger

By Stem Cell Medicine

Date: 10th 11th March 2020 Location: London UK

Regenerative therapies are proving its acceptance in the potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide an illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine, we would be focusing on the pre-clinical, manufacturing, clinical and regulatory aspects of cell therapies and regenerative medicine. This Congress event will be held on 10th and 11th March 2020 in London -UK

Get Register and Download the Agenda at https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/

Key Pointers 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress

Conference Registration

Lets get you sorted! Choose which applies best to you @ https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/register

The rest is here:
4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress - Montana Ledger

Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 – PRNewswire

By Stem Cell Clinics

The report on the global cell therapy market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Read the full report: https://www.reportlinker.com/p05796546/?utm_source=PRN

NEW YORK, Nov. 12, 2019 /PRNewswire/ -- The report predicts the global cell therapy market to grow with a healthy CAGR over the forecast period from 2019-2025. The study on cell therapy market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on cell therapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global cell therapy market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global cell therapy market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings1) Drivers Increasing incidences of cancer across the globe Growing aging patient population Rise in cell therapy transplantations2) Restraints The high cost of transplantation treatment Stringent regulatory policies3) Opportunities Automation in cell therapy

Research Methodology

A) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industry

Our primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.

B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agencies

Segment CoveredThe global cell therapy market is segmented on the basis of cell type, therapy type, application, and end-users.

The Global Cell Therapy Market by Cell Type Stem Cell Differentiated Cell

The Global Cell Therapy Market by Therapy Type Allogenic Therapies Autologous Therapies

The Global Cell Therapy Market by Application Autoimmune Diseases Oncology Dermatology Muscoskeletal Therapies Other Applications

The Global Cell Therapy Market by End-Users Hospitals and Clinics Biotechnology and Pharmaceutical Companies Research Institutes

Company Profiles NuVasive, Inc Kolon TissueGene, Inc. JCR Pharmaceuticals Co., Ltd. Osiris Therapeutics, Inc. Stemedica Cell Technologies, Inc. MEDIPOST Celgene Corporation ANTEROGEN.CO., LTD Vericel Corporation

What does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the cell therapy market.2. Complete coverage of all the segments in the cell therapy market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global cell therapy market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Read the full report: https://www.reportlinker.com/p05796546/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the original here:
Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 - PRNewswire

Canine Arthritis Treatment Market 2018 to Showing Impressive Growth by 2027 | Industry Trends, Share, Size, Top Key Players Analysis and Forecast…

By Stem Cell Clinics

As per the research conducted by Fast. MR, the report titled Canine Arthritis Treatment Market by Treatment Type (Non-steroidal anti-inflammatory Medications (NSAIDs), Opioids and Stem Cell Therapy), By Route of Administration (Oral, and Injectables), By Distribution Channel (Veterinary Hospitals and Clinics, Retail Pharmacies and Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) Global Market Size, Development, Growth and Demand Forecast, 2018-2027 provides current as well as future analysis of the market by evaluating the major applications, advantages, trends, and challenges. The report dives deeper to produce useful insights into Canine Arthritis Treatment Market such as major global regions and key competitors and strategies that can be used for the entry-level player too.

Get Latest Sample for Canine Arthritis Treatment Market @ https://www.fastmr.com/request-s/100

Overview

Canine arthritis is a result of inflammation of the joints, ligament damage, abnormal cartilage development, or damage caused by trauma in dogs. Usually arthritis problem associated with older dogs, however it may occur at early age of dogs, who are facing bone and joint development problem. Arthritis symptoms include stiffness, lameness, or limping after rest; appetite loss or unusual weight gain; inactivity and sleeping more; reluctance to walk, run or climb stairs; unusual urinating in the house; and irritability and other behavioural changes. Since past, According to the American Pet Products Association (APPA), the adoption of pet animal has been increased at a significant rate, about 68% of U.S. households own at least one pet, which adds up to 60.2 Mn dogs and 47.1 Mn dogs, among other animals. Hence, there is a push to increase the standard of living for pets, including higher quality veterinary products. Further, in 2018, US$72.56 Bn was spent on pets, out of which US$ 33.5 Bn was spent for over-the-counter (OTC) medicine in the U.S. Thus, rising companion animal ownership with increase in spending for pet health is creating a growing demand for canine arthritis drugs.

Rising preference of gynaecologist for genetic testing during pregnancy is expected to propel the canine arthritis treatment market growth.

Significant increase in veterinary therapeutic drugs and veterinary regenerative medicines approvals by FDA to repair damaged organs and tissues in animals is expected to drive the canine arthritis treatment market growth. For instance, in November 2018, Chanelle launched Osteopen (pentosan polysulphate sodium) in the UK and Irish markets. Osteopenia is a semi-synthetic polymer with anti-inflammatory properties and capable of modifying the metabolism of the joint structures, which in turn helps to regenerate damaged joint components and reduces the pain.

Furthermore, increase in prevalence of osteoarthritis in dogs will expected to create a demand for canine arthritis drugs market in near future. According to Veterinary Science Development news, one in four of 77.2 million pet dogs in the U.S. are diagnosed with some form of arthritis.

However, certain risks associated with canine arthritis treatment and lack of awareness may restrain the canine arthritis treatment market growth to some extent.

Canine Arthritis Treatment Market Regional Analysis

On the basis of region, North America is gaining significant traction in the canine arthritis treatment market. This is attributed to increase in consumer spending on pet and easy accessibility of treatment and diagnostic methods. There are about 26,000 small animal veterinary practices in the U.S., according to American Animal Hospital Association (AAHA) and the American Veterinary Medical Association (AVMA) which result in a significant increase in veterinary economy the country.

Europe also contribute noteworthy growth in canine arthritis treatment market owing to launch of new treatment by various pharmaceutical companies for canine arthritis. For instance, on March 2019, Medrego, the manufacturer of veterinary regenerative medicine in Northern Europe has launched new Stem Cell Therapy product-CaniCell which has shown tremendous effects on managing osteoarthritis and other degenerative diseases in dogs.

Key players operating in the canine arthritis treatment markets include, Eli Lilly and Company, Boehringer Ingelheim, Chanelle, Zoetis Inc., Medrego, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, and others.

Canine Arthritis Treatment Market-Taxonomy

By Treatment Type

-Non-steroidal anti-inflammatory medications (NSAIDs)

-Opioids

-Stem Cell Therapy

By Route of Administration

-Oral

-Injectables

By Distribution Channel

-Veterinary Hospitals and Clinics

-Retail Pharmacies

-Online Pharmacies

By Region

-North America

-Europe

-Asia Pacific

-Latin America

-Middle East and Africa

Access Complete Canine Arthritis Treatment Market Report@ https://www.fastmr.com/report/100/canine-arthritis-treatment-market

About Us:

FAST.MR is a global market research and business-consulting organization that aims to provide a deep market insight to our clients, which helps them in better decision making in the dynamic environment. We have a team of highly qualified personnel that studies the market in depth to provide our clients with better strategies to stand out in the market.

Contact Us:

Jason Lee

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: sales@fastmr.com

Website: http://www.fastmr.com

Follow Us Facebook, Twitter, Linked In

More https://fastmr.blogspot.com/

Read More https://marketresearchtab.com/

https://marketnewsbizz.com/

See the original post here:
Canine Arthritis Treatment Market 2018 to Showing Impressive Growth by 2027 | Industry Trends, Share, Size, Top Key Players Analysis and Forecast...

Tooth Regeneration Industry 2019 Research on Market Sales, Revenue, Top Companies and Future Development – TheFinanceTime

By Somatic Stem Cells

Latest Report Available at Analytical Research Cognizance, Tooth Regeneration Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.

Tooth regeneration is a stem cell based regenerative medicine procedure in the field of tissue engineering and stem cell biology to replace damaged or lost teeth by redrawing them from autologous stem cells. As a source of the new bioengineered teeth somatic stem cells are collected and reprogrammed to induced pluripotent stem cells which can be placed in the dental lamina directly or placed in a reabsorb able biopolymer in the shape of the new tooth.

Download PDF Sample of Tooth Regeneration Market report @ http://www.arcognizance.com/enquiry-sample/485434

Scope of the Report:The global Tooth Regeneration market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Tooth Regeneration.Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.This report studies the Tooth Regeneration market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Tooth Regeneration market by product type and applications/end industries.

Market Segment by Companies, this report coversUnileverStraumannDentsply Sirona3MZimmer BiometOcata TherapeuticsIntegra LifeSciencesDatum Dental

Brief about Tooth Regeneration Market Report with TOC@ http://www.arcognizance.com/report/global-tooth-regeneration-market-2019-by-company-regions-type-and-application-forecast-to-2024

Market Segment by Regions, regional analysis coversNorth America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, coversDentinDental PulpTooth Enamel

Market Segment by Applications, can be divided intoHospitalsDental ClinicsOthers

Buy The Report @ http://www.arcognizance.com/purchase/485434

Some Points from TOC:

Chapter One: Tooth Regeneration Market Overview

1.1 Product Overview and Scope of Tooth Regeneration

1.2 Classification of Tooth Regeneration by Types

1.2.1 Global Tooth Regeneration Revenue Comparison by Types (2019-2024)

1.2.2 Global Tooth Regeneration Revenue Market Share by Types in 2018

1.2.3 Dentin

1.2.4 Dental Pulp

1.2.5 Tooth Enamel

1.3 Global Tooth Regeneration Market by Application

1.3.1 Global Tooth Regeneration Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 Hospitals

1.3.3 Dental Clinics

1.3.4 Others

1.4 Global Tooth Regeneration Market by Regions

1.4.1 Global Tooth Regeneration Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Tooth Regeneration Status and Prospect (2014-2024)

Chapter Two: Manufacturers Profiles

2.1 Unilever

2.1.1 Business Overview

2.1.2 Tooth Regeneration Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Unilever Tooth Regeneration Revenue, Gross Margin and Market Share (2017-2018)

2.2 Straumann

2.2.1 Business Overview

2.2.2 Tooth Regeneration Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Straumann Tooth Regeneration Revenue, Gross Margin and Market Share (2017-2018)

2.3 Dentsply Sirona

2.3.1 Business Overview

2.3.2 Tooth Regeneration Type and Applications

Chapter Three: Global Tooth Regeneration Market Competition, by Players

3.1 Global Tooth Regeneration Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Tooth Regeneration Players Market Share

3.2.2 Top 10 Tooth Regeneration Players Market Share

3.3 Market Competition Trend

Chapter Four: Global Tooth Regeneration Market Size by Regions

4.1 Global Tooth Regeneration Revenue and Market Share by Regions

4.2 North America Tooth Regeneration Revenue and Growth Rate (2014-2019)

4.3 Europe Tooth Regeneration Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Tooth Regeneration Revenue and Growth Rate (2014-2019)

4.5 South America Tooth Regeneration Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Tooth Regeneration Revenue and Growth Rate (2014-2019)

Chapter Five: North America Tooth Regeneration Revenue by Countries

5.1 North America Tooth Regeneration Revenue by Countries (2014-2019)

5.2 USA Tooth Regeneration Revenue and Growth Rate (2014-2019)

5.3 Canada Tooth Regeneration Revenue and Growth Rate (2014-2019)

5.4 Mexico Tooth Regeneration Revenue and Growth Rate (2014-2019)

About US:

http://www.arcognizance.com is an initiation in this new era of analysis @ thought. We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of new analytics based on the data collection facilities of big data, the face of business research facilities has changed drastically. With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the out of the box developments in the market.

Contact US:

Name: Analytical research cognizance

Address: 100 Church Street,

8th floor, Manhattan,

New York 10007

Phone:+1 (646) 434-7969 +91 90967 44448

Email: enquiry@arcognizance.com

View original post here:
Tooth Regeneration Industry 2019 Research on Market Sales, Revenue, Top Companies and Future Development - TheFinanceTime

The Fast Pace of CAR T-Cell Innovation Caused an Array of Challenges in Treatment – AJMC.com Managed Markets Network

By Uncategorized

The evidence shows that chimeric antigen receptor (CAR) T-cell therapies are effective, but the price tags on these treatments are high and have raised concerns about how many patients will get treated. During a discussion at The American Journal of Managed Cares Patient-Centered Oncology Care meeting, held Friday in Philadelphia, panelists outlined the efficacy of the 2 FDA-approved therapies, Medicare reimbursement for CAR T-cell therapies, and the pace of innovation in healthcare.

In children, tisagenlecleucel (Kymriah) has successfully treated children and young adults, up to age 25, with relapsed or refractory acute lymphoblastic leukemia, explained Shannon L. Maude, MD, PhD, assistant professor of pediatrics in the Division of Oncology at the Childrens Hospital of Philadelphia, and medical director of the Center for Cellular Immunotherapies at the University of Pennsylvania Perelman School of Medicine.

In the trials that led to FDA approval, patients treated with tisagenlecleucel had a remission rate of 81% after relapsing more than once after the best standard of care. In some of the longer-term data now being seen, patients who went into remission have a relapse-free survival rate of 66%.

The other FDA-approved therapy, axicabtagene ciloleucel (Yescarta), is indicated in adults with diffuse large B-cell lymphoma (DLBCL), which typically affects people in their 60s and 70s, said John W. Sweetenham, MD, FRCP, FACP, FASCO, professor of medicine and associate director of clinical affairs at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. For 15 to 20 years, treatment for disease has be relatively the same: chemotherapy is front line followed by a bone marrow transplant. But if those 2 treatments are unsuccessful, the patients had essentially no other options.

Now, there have been extraordinary responses with CAR T-cell therapy, he said. There are patients who, in the past, he would have anticipated have a bad outcome after relapsing, who have now survived more than a year after treatment.

This treatment is like nothing weve ever seen before in terms of its ability to turn very sick people around, Sweetenham said.

However, since these therapies are so different, there are still plenty of unknowns. There have not been any randomized trials to compare the CAR T-cell therapy treatment with more standard treatments, for instance.

As a result of how successful CAR T-cell therapies have been and the uniqueness of them, they cost upwards of $373,000 per treatmentthe good news, said Erika Miller, JD, senior vice president and counsel at CRD Associates, is that patients only need the treatment one time. The problem is that regulators and legislators are concerned about safeguarding the Medicare trust fund, and these therapies are a big hit, financially.

There is concern that if Medicare pays the full cost, that it is sending a signal to drug makers that the price tag is not a problem and they might even be able to ask for more for the next treatment.

[Regulators and legislators] are concerned about how many patients are going to get this, Miller said. Theyre afraid of a tsunami. And then, this is all happening at the same time that everyone in Washington [DC] is talking about the price of drugs.

She echoed Sweetenham and Maudes comments that everyone is still waiting to see how effective the treatments will be in the long term. In addition, a greater concern is that there are other CAR T-cell therapies in the pipeline, which will only add to the costs.

Medicare doesnt change on a dime, she said. It takes them a long time to change their policy. They have mechanisms for payment that have been in place for a long time that they are reluctant to change.

The pace of innovation has been, perhaps, too fast. It has outpaced changes in payment, but also, in some ways, were ahead of the evidence, Sweetenham said.

We dont want to end up in a situation where patients are potentially missing out on effective treatment because its taking us too long to get the evidence that we really need, he added.

Putting together clinical trials is complicated and expensive, and researchers need a solid partnership with all the stakeholders in terms of getting needed clinical trials moving, Sweetenham said.

Maude added that when trials are set up, they need to be optimized so we can identify which patients will benefit the most from CAR T-cell therapies and, thus, improve the outcomes that are already seen. There is additional cost in setting up those types of trials, but they will be more cost effective in the long run, she said.

Moving forward, improving patient access to these treatments is critical, Miller said. The cost of CAR T-cell therapies is so high that academic medical centers are losing out on more than $100,000 for each patient treated. As a result, there are some centers that are deciding not to offer CAR T-cell therapy.

Maude and Sweetenham also highlighted the access challenges. Since so few centers offer CAR T-cell therapy, patients often have geographic barriers and have to drive long distances in order to get treatment. Patients who have commercial insurance tend to have less trouble getting the treatment approved than patients who are in Medicare.

While the current administration has been reluctant to pay the full price tag for these therapies, it has shown it is very focused on promoting innovation, Miller said. Theres recognition that theres innovation here that cant be choked off, she said. The administration is listening, and there has been some progress with the increased new technology add-on payment, but with an election next year, there could be a new administration in the White House with a different perspective.

When asked to peer into the future, Miller predicted that there would be a payment model for CAR T or cellular therapies being tested. Next year there might be a CAR T-cell therapy for multiple myeloma, which has a large patient base, so there will be more pressure on CMS to create a payment model.

Maude and Sweetenham are both hoping to see more longer-term follow-up data and better predictions about which patients will benefit the most. Sweetenham is also anticipating that these treatments will move more into the outpatient setting and hopes to see patients getting better access to the treatments.

Pessimistically, I havent seen the field really move that far in 5 years, Sweetenham said.

Read the original:
The Fast Pace of CAR T-Cell Innovation Caused an Array of Challenges in Treatment - AJMC.com Managed Markets Network

Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global…

By Uncategorized

Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine 15,000 babies are born with sickle cell disease every year in Ghana

ACCRA, Ghana, Nov. 11 /CSRwire/ - Today, the Government of Ghana announced the availability of hydroxyurea for the treatment of people with sickle cell disease (SCD), marking the official launch of a first of its kind public-private partnership to improve the diagnosis and accelerate treatment for people with SCD. The launch follows the signature of a Memorandum of Understanding in January among the Ministry of Health of Ghana, Ghana Health Service, the Sickle Cell Foundation of Ghana and global medicines company Novartis to create a holistic approach to help manage the disease. Ghana is the first African country to commit to offering the global standard of care for their people with SCD.

I am proud of this bold partnership, and it is my hope that, through this collaboration, we will help ease the pain and improve the lives of people living with sickle cell disease in our country. We are committed to put SCD among the priorities on our national health agenda and to take the necessary steps to make treatment broadly available through our National Health Insurance Scheme, bringing much-needed relief to families struggling to cover the cost of care for their loved ones, said H.E. Alhaji Dr. Mahamudu Bawumia, Vice President of the Republic of Ghana. Our collective goal is to reimagine what the future could look like for people with sickle cell disease: where children do not need to miss out on school or be singled out; where young adults can have equal opportunity for employment; and where families can flourish and continue to be the bedrock of our civil societyin a nutshell, we will make every effort to normalize sickle cell disease within the Ghanaian society.

To date, Novartis has delivered more than 20 000 treatments of hydroxyurea. Initially, the therapy will be made available through 11 trained treatment centers, as well as through private distribution channels, and is expected to cover the needs of patients for up to 12 months. The partners aim to open more treatment centers by the end of the year, and Novartis is committed to delivering a total of 60 000 treatments. Discussions are aleady underway for inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme, as well as prioritizing SCD as a national program.

Hydroxyurea is a commonly used medicine for patients with SCD in developed countries, and is approved for use in both adults and children. In October 2018, the Ghana FDA granted marketing authorization to Novartis hydroxyurea, making it the first time that hydroxyurea will be available for this indication in Ghana. A recent study, published in the New England Journal of Medicine3indicates that hydroxyurea treatment is effective and safe in children with SCD in sub-Saharan Africa and reduces the incidence of pain events (vaso-occlusive crises), malaria, blood transfusions, and death.

All the traditional names by which SCD is known allude to the episodes of severe pain experienced by people with the disease, said Prof. Kwaku Ohene-Frempong, MD, President of the Sickle Cell Foundation of Ghana and Program Coordinator for the National Newborn Screening Program for Sickle Cell Disease. Hydroxyurea is a drug with proven efficacy in reducing pain episodes and other complications of the disease. Currently, the highest standard of care for people with SCD starts with early diagnosis through newborn screening followed by penicillin prophylaxis to prevent early death from infection, and hydroxyurea therapy to ease the pain, prevent other complications and improve quality of life.

At the same time, Novartis has committed to develop a child-friendly formulation of hydroxyurea and has announced plans to conduct two clinical trials in Ghana and Kenya for its next-generation treatment for SCD, crizanlizumab. Crizanlizumab is a novel targeted biologic therapy that is expected to help reduce pain crises in people with SCD. The trials are expected to start in 2020; this will be the first time that a biologic therapy, which is not a vaccine, enters multicenter clinical trials in sub-Saharan Africa (excluding South Africa)4.

Novartis is deeply committed to reimagining medicine for patients in Ghana and across Africa, said Vas Narasimhan, MD, CEO of Novartis. Building on our long heritage of addressing malaria and leprosy in Africa, were excited to help improve the diagnosis and treatment of people with sickle cell disease here in Ghana. Novartis is proud to join this pioneering partnership, which could accelerate efforts to forge a healthier future for children across the continent.

Sickle cell disease is recognized by the World Health Organization as a public health priority and a neglected health problem in sub-Saharan Africa. Approximately 80% of individuals with

SCD globally are born in sub-Saharan Africa, and there is evidence to suggest that more than half of affected individuals may die before the age of five due to preventable complications. In Ghana, it is estimated that 15 000 babies are born with sickle cell disease every year2.

The five-year partnership aims to improve and extend the lives of people with SCD through a comprehensive approach to screening and diagnosis; treatment and disease management; training and education; and elevating basic and clinical research capabilities. Specifically, the partners aim to collaborate on field testing and implementation of SCD treatment guidelines, the establishment of centers of excellence across regions and the implementation of newborn screening at these centers. In addition, partners plan to employ digital technologies to monitor and evaluate patient registration, report real-time data and help ensure safe large scale roll-out of medicine.

In parallel, Novartis is working with Zipline, a California-based automated logistics company, to make sickle cell treatments widely available, especially in rural areas. Zipline is already operating two distribution centers in Ghana, in Omenako and Asante Mampong, with plans to open two more in the near future.

In addition, in order to help further ensure a sustainable supply of high quality hydroxyurea, Novartis has entered a strategic collaboration with Olon, a manufacturer based in Italy that supplies the active ingredient for the drug. We are proud to collaborate with Novartis and its partners to help make hydroxyurea more broadly available and in a sustainable way, said Paolo Tubertini, CEO of Olon.As a demonstration of our commitment to patients with sickle cell disease and this program, we will also contribute, without cost, the active ingredient to cover approximately 12 000 thousand treatments. Our hope is to continue to meet the needs and challenges of those living with sickle cell disease and their families to improve access to quality health care.

About Sickle Cell Disease

Sickle cell disease is a deblitating, inherited blood disorder. It causes affected red blood cells to become sickle-shaped, stiff and fragile easily breaking apart. Blood vessels and blood cells become sticky due to damage caused by sickle cells and ongoing chronic inflammation5,6. That leads to blood cells sticking to each other and to the blood vessels and causing blockages called vaso-occlusion - which can lead to the acute episodes of pain (known as sickle cell pain crises or vaso-occlusive crises), stroke and other life-threatening complications5,7. It is a lifelong illness that can put an emotional, physical, and financial burden on patients and their families8,9.

SCD is a global health problem, with the highest burden of disease concentrated in sub-Saharan Africa. In countries in West, Central and East Africa, the prevalence of the sickle cell gene is between 10 to 30 percent, while in some areas it is as high as 45%10. It is estimated that approximately 1 000 children in Africa are born with SCD every day and more than half die before they reach five years of age11. This is due primarily to lack of early diagnosis through newborn screening, penicillin prophylaxis, parental education, and comprehensive care. In resource-poor countries, more than 90 percent of children with SCD do not survive to adulthood12. Despite the adoption by the WHO of an SCD strategy for Africa in 2010, the disease is largely absent from the global or national health agenda.

References

Read this article:
Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global...

→←